| |
1.Kuo M-C, Su P-J, Huang C-C, Luo H-L, Chiu T-J, Li S-H, Wu C-C, Liu T-T, Cheng Y-T, Kang C-H and Su Y-L (2020) Safety and Efficacy of Immune Checkpoint Inhibitors for Patients With Metastatic Urothelial Carcinoma and End-Stage Renal Disease: Experiences From Real-World Practice. Front. Oncol. 10:584834. doi: 10.3389/fonc.2020.584834
2.Kuo MC, Liu CT. Effect of immune checkpoint inhibitors in gynecologic cancer associated with defective mismatch repair and a rare immunotherapy-related adverse event. J Cancer Res Pract 2021;8:73-7. doi: 10.4103/JCRP.JCRP_4_21
|
|
